Overview

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This study assessed the long term safety data for the use of tobramycin inhalation powder in patients suffering from cystic fibrosis who have a chronic pulmonary infection with Pseudomonas aeruginosa.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Tobramycin